The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Xolair SC Pen Versions Approved in Japan: Novartis
Novartis Pharma said on March 8 that it has obtained Japanese regulatory approval for subcutaneous autoinjector pen versions of its asthma and chronic hives treatment Xolair (omalizumab). Approval was granted on March 5 to Xolair for SC injection pen 75…
To read the full story
Related Article
- Xolair SC Pen Versions Go on Sale in Japan: Novartis
August 23, 2024
- Japan’s 1st Stelara Biosimilar Gets Listing, New Kit Products Too
May 21, 2024
BUSINESS
- Tokyo Court Tosses Nihon Generic’s Suit over Bayer’s Xarelto Patent Communications
December 18, 2025
- Velcade Generics Widen Labels to Mantle Cell Lymphoma
December 18, 2025
- Kowa Releases Glaucoma Drug Gla-Alpha in Malaysia
December 18, 2025
- Xarelto Generics Win Adult, Pediatric VTE Indication Expansions
December 18, 2025
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…